Clinical Trial Update: Rituximab for GVHD [Phase 2]

View source ↗

Summary

Phase 2 trial of Rituximab for graft-versus-host disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Graft vs Host Disease, Alogenic Hematopoietic Transplant | Phase 2 | Status: WITHDRAWN